Home › Compare › CVONF vs ABBV
CVONF yields 2857.14% · ABBV yields 3.09%● Live data
📍 CVONF pulled ahead of the other in Year 1
Combined, CVONF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CVONF + ABBV for your $10,000?
Carnarvon Energy Limited explores for, develops, and produces oil and gas in Australia. The company owns interests in the Dorado project located in the Bedout Sub-basin permits of Western Australia; the Buffalo project situated in Bonaparte Basin; and the Labyrinth project located in the Roebuck Basin in the North West Shelf of Western Australia. It also holds interests in the Taurus project located in the North West Shelf; the Condor and Eagle projects located in the Vulcan Sub-Basin; the Outtrim project located in the Exmouth Sub-Basin; and the Pepper project that is situated in Barrow Sub-basin of the Northern Carnarvon Basin. The company was formerly known as Carnarvon Petroleum Limited and changed its name to Carnarvon Energy Limited in November 2021. Carnarvon Energy Limited was incorporated in 1983 and is headquartered in West Perth, Australia.
Full CVONF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.